In NSCLC, multiple studies have described TROP2 overexpression in patients with NSCLC, ranging from 42% to 100% of patients tested demonstrating intratumoral TROP2 expression by IHC [111,112,113,114]. The gene discussed is TACSTD2; the disease is non-small cell lung carcinoma.